SCHEMBL4020218

SCHEMBL4020218

Cc1cccc(C2[C@@H](C(=O)c3ccccc3)CN(CC(=O)N3CCNCC3)C[C@@H]2C(=O)c2ccccc2)c1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.39
LMNA P02545 3/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
SIGMAR1 Q99720 1/20 0.39
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 1/20 0.36
ALOX15 P16050 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HTR2C P28335 2/20 0.36
ADRB1 P08588 1/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
MAPK1 P28482 2/20 0.36
GAA P10253 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TSHR P16473 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HTT P42858 1/20 0.34
KIF11 P52732 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4020222 1.00 MAPT (0.39) MAPTLMNAKMT2AMEN1SIGMAR1
SCHEMBL4021226 0.89 KMT2A (0.42) MAPTLMNAKMT2AMEN1ALDH1A1
SCHEMBL4023694 0.89 ALDH1A1 (0.44) MAPTLMNAKMT2AMEN1ALDH1A1
SCHEMBL4021968 0.89 ALDH1A1 (0.44) MAPTLMNAKMT2AMEN1ALDH1A1
SCHEMBL4021972 0.89 ALDH1A1 (0.44) MAPTLMNAKMT2AMEN1ALDH1A1
SCHEMBL4021223 0.89 KMT2A (0.42) MAPTLMNAKMT2AMEN1ALDH1A1
SCHEMBL4022026 0.88 MEN1 (0.45) MAPTLMNAKMT2AMEN1ALDH1A1
SCHEMBL4022022 0.88 MEN1 (0.45) MAPTLMNAKMT2AMEN1ALDH1A1
SCHEMBL4022415 0.84 GRIN2B (0.38) MAPTLMNAKMT2AMEN1ALDH1A1
SCHEMBL4021213 0.84 GRIN2B (0.38) MAPTLMNAKMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US claimed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US claimed
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US disclosed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161674-A1 Certain chemical entities, compositions, and methods TP53, VHL, RB1 MAPT 3009/4885LMNA 315/4885KMT2A 2820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.